Blue Owl Technology Finance (OTF) maintains a buy rating despite a recent nearly 15% price drop and underperformance. Its net interest income remains stable at $0.29 per share, supported by floating-rate debt and potential Federal Reserve rate hikes. The company's net asset value improved by $0.14 per share due to realized and unrealized gains and share repurchases, indicating better portfolio quality. Key risks include unsustainable dividend coverage, rising debt costs, and a large debt maturity in 2027, but OTF's deep price-to-book value discount suggests strong upside potential for investors.
Blue Owl Technology Finance stock is the subject, with Pluang's Financials-sector snapshot providing context. For readers following Financials, as of Nov 10, 2026 18:42 WIB, 90 of 142 priced US Financials stocks rose while 45 fell. Notable movers include UBS at USD 49.94 with a 1-day change of +2.00% and 100% sell order activity, Prospect Capital Corporation (PSEC) at USD 1.54 with +1.99% and 80% buy order activity, and ING at USD 33.75 with a +1.66% change and a typical hold time of 97 days on Pluang.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
